Vol 6 Issue 7

CELL AND GENE THERAPY INSIGHTS

Vol 6 Issue 7

Cell and Gene Therapy Insights Vol 6 Issue 7

Download PDF

Featuring

Issue Spotlight: Market access: evolving commercialization trends and strategies
Vector characterization and validation
Other articles

Market access: evolving commercialization trends and strategies

Neil Palmer

Guest Editor:

Neil Palmer, President and Principal Consultant at PDCI Market Access

Foreword

Under construction: roadmaps for HTA, pricing and reimbursement of cell and gene therapies

Under construction: roadmaps for HTA, pricing and reimbursement of cell and gene therapies

3 September 2020

Expert Insight

Challenges and proposed solutions to value assessment and reimbursement of CAR-T therapies in Europe

Challenges and proposed solutions to value assessment and reimbursement of CAR-T therapies in Europe

Clare Hague, Martin Price

Commentary

The heart of market access: opportunities and challenges for cell and gene therapy development for orphan and prevalent cardiovascular diseases

The heart of market access: opportunities and challenges for cell and gene therapy development for orphan and prevalent cardiovascular diseases

23 September 2020

Joint collaborations and future perspectives for gene therapies.

Joint collaborations and future perspectives for gene therapies.

M Dabbous, B Borissov, C Dussart et al.

3 September 2020

Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)

Bringing advanced therapies to the clinic: the Swedish National ATMP Consortium (CAMP/SWElife ATMP)

Stefan Scheding, Heather Main, Pontus Blomberg

Challenges in the adoption of regenerative medicine therapies, meeting summary

Challenges in the adoption of regenerative medicine therapies, meeting summary

M Chaddah, S McMahon, J Kusena et al.

Innovative payments for innovative therapies: adopting value-based models in the regenerative medicines & advanced therapy sector

Innovative payments for innovative therapies: adopting value-based models in the regenerative medicines & advanced therapy sector

Janet Lynch Lambert

Interview

How should health technology assessment of ATMPs evolve in Europe?

How should health technology assessment of ATMPs evolve in Europe?

2 September 2020

From rare monogenic diseases to Parkinson’s: market access considerations for gene therapy across large and small indications

From rare monogenic diseases to Parkinson’s: market access considerations for gene therapy across large and small indications

HTA evolution in Canada: considerations for cell and gene therapy

HTA evolution in Canada: considerations for cell and gene therapy

Vector characterization and validation

Interview

Priorities for AAV vector analytics development

Priorities for AAV vector analytics development

Christine Le Bec

Commentary

The right analytical toolbox is key to moving your pipeline forward

The right analytical toolbox is key to moving your pipeline forward

Journal articles

Editorial

Fighting a global pandemic with an army of robots

Fighting a global pandemic with an army of robots

Rennos Fragkoudis, Nikolaos Pantidos

Innovator Insight

Downstream purification of adeno-associated virus for large-scale manufacturing of gene therapies

Downstream purification of adeno-associated virus for large-scale manufacturing of gene therapies

Mikhail Goldfarb, Orjana Terova

24 September 2020

Commentary

Two new capture options for improved purification of large mRNA

Two new capture options for improved purification of large mRNA

P Gagnon, B Goričar, Š Peršič et al.

1 September 2020

Chemogenetics: drug-controlled gene therapies for neural circuit disorders

Chemogenetics: drug-controlled gene therapies for neural circuit disorders

Scott M Sternson, David Bleakman

8 September 2020

Interview

Keys to remaining at the forefront of innovation in cell and gene therapy

Keys to remaining at the forefront of innovation in cell and gene therapy

Manuel Carrondo

Commercial Insights

Cell & Gene Therapy Commercial Insight - June 2020

Cell & Gene Therapy Commercial Insight - June 2020

Mark Curtis, Richard Philipson